Published date: Mar 10 2019

Journal Title: KnE Life Sciences

Issue title: The UGM Annual Scientific Conference Life Sciences 2016

Pages: 8–18

DOI: 10.18502/kls.v4i11.3847

M Putri Ekasarimarlita.putri.ekasari@gmail.com

N Munif Yasin

S Ari Kristina

Z Ikawati

Nausea and vomiting are chemotherapy adverse events that influence breast cancer patient’s quality of life. Antiemetic regimen as premedication was given to prevent those adverse events and need to be evaluated. This study aimed to present the effectiveness of antiemetic treatment among breast cancer patients in the inpatient unit, Rumah Sakit Umum Pusat Dr. Sardjito [Central Public Hospital Dr. Sardjito] Yogyakarta, Indonesia.
A cohort study was used in this study during July 2008 to January 2009. Thirty-one breast cancer patients, who are receiving antiemetic therapy and having no disease that induced nausea and vomiting were involved, signed informed consent and had been followed by before-post chemotherapy. The data was gained from chemotherapy and antiemetic regimens, medical records, patient’s interviews, and finally analyzed
using descriptive, evaluative approach. This study presented that antiemetic treatment among breast cancer patient in the inpatient unit was 61.40 % ineffective reducing incidence of nausea vomiting events. The majority of cases of nausea and vomiting onset among patients were acute-delayed (56.2 %; 52.0 %), severity of nausea and vomiting laid mostly in the second level (54.54 %; 52.00 %), and appropriateness antiemetic treatment complied to NCCN guideline 2007 and ASCO guideline 2006 was only applied in low emetic risk of chemotherapy-induced nausea and vomiting. Antiemetic regimens that had been implemented need to be evaluated because of majority cases of nausea and vomiting were the acute-delayed type, level two of severity and inappropriateness of international guideline. This study should be followed with the future study of the evaluation of the effectiveness of another medication supported the patient in receiving chemotherapy.

Keywords: Antiemetic, Breast cancer, Effectiveness, Nausea, Vomiting.

[1] WHO. Cancer [Internet]. 2008 [cited 2008 Dec 1]. Available from: http://www.who.int/ cancer/en/


[2] WHO. WHO’s fight against cancer strategies that prevent, cure, & care. 2008. p.3. [cited 2009 Feb 23] http://www.who.int/cancer/publications/fight_against_cancer/ en/[3] TIM RS Kanker Dharmais. Penataksanaan kanker payudara terkini. [Implementing the latest breast cancer]. YOI, Yogyakarta; 2003. p. 87, 94. [in Bahasa Indonesia] https://books.google.co.id/books?id=YmfVskk6QOgC&dq=Tim+Penanggulangan+ Dan+Pelayanan+Kanker+Payudara+Terpadu+Paripurna+R.S.+Kanker+Dharmais. +Penataksanaan+Kanker+Payudara+Terkini.+2003.&hl=id&source=gbs_navlinks_s


[4] National Cancer Institute. Nausea and vomiting (PDQ®)–health professional version [Internet]. 2008 [cited 2009 Jan 20]. Available from: https://www.cancer.gov/aboutcancer/treatment/side-effects/nausea/nausea-hp-pdq


[5] Alsagaff H. Kanker paru dan terapi paliatif. [Lung cancer and palliative therapy]. Surabaya, Airlangga Universitas Press; 1995. p. 143–144, 295–297. [in Bahasa Indonesia] https://books.google.co.id/books/about/
Kanker_paru_dan_terapi_paliatif.html?id=0LqQnQAACAAJ&redir_esc=y


[6] DiPiro JT, Talbert RL, Yee GC, Matzkee GR, Wells BG, Posey M. Pharmacotherapy 7th ed. United States of America, The McGraw-Hill Companies; 2008. p. 295–297 http: //fac.ksu.edu.sa/sites/default/files/Pharmacotherapy_Handbook_7th_Edition.pdf


[7] As Shidiq FH. Profil pasien kanker payudara di RS Dr.Sardjito periode 2003–2004. [Profile of breast cancer patients in Dr. Sardjito Hospital period 2003-2004]. [Thesis]. Faculty of Medicine, Universitas Gadjah Mada Indonesia; 2006. p.17–18. [in Bahasa Indonesia]. [Unpublished].


[8] National Cancer Institute of Canada. Canadian cancer statistics [Internet]. Toronto, Canada; 2007. p. 116. Available from: www.canceradvocacy.ca/ann/special.html/ 4915/Canadian+Cancer+Statistics+2007.pdf


[9] Ihbe-Heffinger. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol [Internet]. 2004 Mar 1 [cited 2016 Dec 2014];15(3):526–536. Available from: http://annonc.oupjournals.org/cgi/doi/10.1093/annonc/mdh110


[10] Fabi A, Barduagni M, Lauro S, Portalone L, Mauri M, Marinis F. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer [Internet]. 2003 Mar [cited 2016 Dec


14];11(3):156–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12618925 [11] Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis: Clinical practice guidelines in OncologyTM. JNCCN J Natl Compr Cancer Netw [Internet]. 2007;5(1):12–33. https://www.ncbi.nlm.nih.gov/pubmed/19460282


[12] Jordan K, Kasper C, Schmoll H-J. Chemotherapy-induced nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer [Internet]. 2005 Jan [cited 2016 Dec 14];41(2):199–205. http://www.ncbi.nlm.nih.gov/ pubmed/15661543